The primary cause of death in ALS is respiratory failure. As motor neurons die, the muscles responsible for breathing, especially the diaphragm, progressively weaken until they can no longer inflate the lungs. Median survival is roughly 2.5 years from symptom onset, though this varies widely depending on where the disease starts and how it’s managed.
How ALS Leads to Respiratory Failure
ALS destroys the motor neurons that control voluntary muscles. The diaphragm, the dome-shaped muscle beneath your lungs that does most of the work of breathing, is one of the most critical targets. As the neurons supplying the diaphragm die off, the muscle becomes denervated, meaning it loses its nerve signals and gradually becomes paralyzed. Needle examinations of the diaphragm in ALS patients show severe denervation, and imaging confirms that the diaphragm stops moving normally.
This creates a slow-motion crisis. With a weakened diaphragm, the lungs can’t fully expand, so less oxygen gets in and less carbon dioxide gets out. CO2 builds up in the blood, a condition that initially causes morning headaches, fragmented sleep, and daytime drowsiness. Over time, the imbalance worsens. In some patients, ventilatory failure is actually the first noticeable symptom of ALS, before any limb weakness appears at all.
The terminal phase typically involves progressive breathlessness that becomes harder to manage. Comfort-focused care at this stage centers on medications that ease the sensation of air hunger and anxiety, keeping the patient as comfortable as possible.
Aspiration Pneumonia
ALS also attacks the muscles of the throat and tongue, making swallowing increasingly difficult. Up to 85% of people with ALS develop some degree of swallowing difficulty as the disease progresses. When food, liquid, or saliva slips into the airway instead of the esophagus, it can seed a lung infection called aspiration pneumonia.
Aspiration pneumonia doesn’t happen to every ALS patient, but when it does, it’s often fatal quickly. Research from the Mayo Clinic found a mean survival of just two months after an episode of aspiration pneumonia. The strongest risk factor was nursing home residence, which carried a sevenfold increase in risk, likely reflecting more advanced disease and reduced ability to manage swallowing safely.
Sudden Cardiac Events
A less widely known cause of death in ALS is sudden circulatory collapse, particularly in patients who are already on ventilators. A study of 23 ventilator-dependent ALS patients found that six died from sudden cardiac arrest, with five of those deaths occurring during sleep at night.
The underlying problem appears to be autonomic dysfunction. The autonomic nervous system, which controls heart rate, blood pressure, and other functions you don’t consciously manage, becomes dysregulated in advanced ALS. Patients show signs of continuous sympathetic overdrive: persistently elevated stress hormones, constant rapid heart rate, and dramatic blood pressure swings. Episodes of sudden blood pressure drops during sleep, without the normal compensatory increase in heart rate, can trigger circulatory collapse. This means that even when a ventilator solves the breathing problem, the nervous system’s ability to maintain basic cardiovascular stability can fail.
Malnutrition and Weight Loss
Difficulty swallowing isn’t just a pneumonia risk. It also makes eating exhausting and sometimes frightening, leading to reduced calorie intake at exactly the wrong time. About half of ALS patients are hypermetabolic, burning roughly 20% more calories at rest than their body size would predict. So the disease simultaneously makes it harder to eat and increases the body’s energy demands.
The result is progressive weight loss and malnutrition, which are directly associated with shorter survival. Even patients who maintain their oral intake can lose weight because the hypermetabolic state outpaces what they consume. Feeding tubes can help maintain nutrition when swallowing becomes unsafe, but the metabolic mismatch remains a persistent challenge throughout the disease.
Why Onset Type Matters
Where ALS first appears in the body significantly affects how quickly it becomes life-threatening. About 25% of patients have bulbar-onset ALS, meaning the disease starts in the muscles controlling speech and swallowing. These patients tend to progress faster than those with limb-onset ALS, who first notice weakness in an arm or leg. Bulbar-onset patients have a median survival of about 27 months from first symptoms and face earlier swallowing and breathing problems, which are the two pathways most directly tied to death.
Limb-onset patients generally have more time before respiratory muscles are affected, though the disease eventually spreads to involve breathing in nearly all cases regardless of where it starts.
How Breathing Support Changes the Timeline
Non-invasive ventilation, typically a bilevel positive airway pressure (BiPAP) machine worn as a mask during sleep and eventually during the day, is the single most impactful intervention for extending survival. A large study of over 400 BiPAP users found they survived a median of 21 months compared to about 14 months for non-users, a difference of roughly 8 months, representing a 52% increase in survival duration.
This benefit comes from offloading work from the failing diaphragm, improving gas exchange, and reducing the CO2 buildup that accelerates decline. Starting ventilation earlier and using it consistently provides the greatest benefit. Invasive ventilation through a tracheostomy can sustain breathing indefinitely but introduces its own set of complications, including the autonomic instability and sudden cardiac risks described above. Most patients ultimately choose comfort-focused care over indefinite mechanical ventilation, making the transition from breathing support to palliative management one of the most important decisions in ALS care.